MODERNA INC. DL-,0001 WKN: A2N9D9 ISIN: US60770K1079 Forum: Aktien Thema: Hauptdiskussion

Nein schon lange nicht mehr

Die Aktie könnte auf 200 steigen, und BioNTech wird bei geringen Impulsen ähnlich reagieren.

Hm erste Mal mit Long drinne und nur minus denkt ihr es geht heute noch hoch

Bin mit Long mal 7 drin und es läuft blendend

Omg bad news was war das für ein Strohfeuer?

Hallo an alle Investierten 👋🏻. Ich wünsche allen endlich aus Ihrem Minus rauszukommen und den anderen noch fettere Gewinne 🎉

Müllst du hier auch alles voll, reicht es nicht im BionTech Forum 🙄

An der Börse genügt Glaube nicht. Wissen ist wichtiger.

Ai, ai: Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Moderna (MRNA) TipRanks Newsroom Sep 29, 2026, 07:00 AM Moderna (MRNA) J.P. Morgan analyst Jessica Fye maintained a Sell rating on Moderna yesterday. The company’s shares closed last Monday at $197.28. According to TipRanks.com, Fye is a 4-star analyst with an average return of 4.8% and a 52.6% success rate. Fye covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Vertex Pharmaceuticals, and Mirum Pharmaceuticals. Moderna has an analyst consensus of Hold, with a price target consensus of $109.19.

Interessant: Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit 21:38 28/09/2026 By Blake Brittain Sept 28 (Reuters) - A federal judge in Delaware on Monday rejected Pfizer , BioNTech and Moderna's requests to dismiss patent lawsuits filed against them by Bayer's Monsanto unit over the messenger RNA technology used in their COVID-19 vaccines. US Circuit Judge William Bryson, sitting at the court by designation, said that the vaccine makers failed to show at an early stage of the case that the patent at issue was invalid or not infringed by their shots Spokespeople for the vaccine makers did not immediately respond to requests for comment on the decision "We are pleased with the court’s decision and remain confident in our position that Bayer’s patented innovations were used without authorization," Bayer said in a statement Bayer sued the companies in January for allegedly copying technology developed by Monsanto in the 1980s for strengthening mRNA in crops and using it to stabilize the genetic material in their vaccines The vaccine makers argued that their manufacturing processes worked differently than Bayer's technology Moderna also argued that the patent covered an unpatentable "law of nature" Bayer has also filed a separate lawsuit against Johnson & Johnson over the patent in New Jersey. The case is ongoing.

Leute vielleicht die noch mehr an das Unternehnen glauben.

Ach wie ist das schön 🤗… so viele Neider hier aber bleibt uns weiterhin treu und schaut zu wie wir Money machen 😘

Weil hier keiner mehr kauft. Wer ist schon so gestört, dass er bei 175€ einsteigt

wenn du danach gehst, schreibe mit di marco ( das kleine Würstchen) und der weiße Hai( dauerbreit)